Condition Lookup

Prader-Willi Syndrome

Specialty: Genetics

Symptoms:
hypotonia (low muscle tone) in infancy; feeding difficulties in infancy; hyperphagia (excessive hunger); obesity; intellectual disabilities; behavioral problems; short stature; small hands and feet; hypogonadism; distinct facial features

Root Cause:
Caused by loss of function of genes on the paternal copy of chromosome 15, typically due to a deletion, uniparental disomy, or imprinting defect.

How it's Diagnosed: videos
Clinical evaluation, genetic testing (methylation analysis to confirm abnormal imprinting on chromosome 15).

Treatment:
Multidisciplinary care, including strict dietary supervision, behavioral therapy, physical therapy, and hormone replacement therapy (e.g., growth hormone).

Medications:
Growth hormone therapy (to improve growth, body composition, and physical strength), and occasionally medications for behavioral issues (e.g., selective serotonin reuptake inhibitors [SSRIs] for compulsive behaviors or mood stabilization).

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 15,000 to 1 in 30,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
No specific risk factors beyond genetic inheritance patterns; sporadic occurrence.

Prognosis: The expected outcome or course of the condition over time.
Lifespan is generally reduced due to complications of obesity or associated conditions, but with proper management, individuals can achieve a relatively good quality of life.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Severe obesity, type 2 diabetes, sleep apnea, cardiovascular disease, scoliosis, and behavioral issues.

Angelman Syndrome

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Imprinting Disorders

Symptoms:
severe developmental delays; speech impairment or absence of speech; frequent laughter or smiling; ataxia (balance and movement difficulties); seizures; intellectual disability; distinctive facial features; sleep disturbances

Root Cause:
Caused by loss of function of the UBE3A gene on the maternal copy of chromosome 15, typically due to a deletion, uniparental disomy, or mutation.

How it's Diagnosed: videos
Clinical evaluation, genetic testing (methylation analysis, UBE3A gene testing, and fluorescence in situ hybridization [FISH]).

Treatment:
Supportive care, including physical therapy, speech therapy, behavioral interventions, anticonvulsants for seizures, and sleep management strategies.

Medications:
Anticonvulsants (e.g., valproic acid, levetiracetam ) for seizure control; melatonin or sedative medications for sleep disturbances.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 12,000 to 1 in 20,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
No specific risk factors beyond genetic inheritance patterns; sporadic occurrence.

Prognosis: The expected outcome or course of the condition over time.
Life expectancy is near normal, but individuals require lifelong supportive care due to severe developmental disabilities.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Seizures, sleep problems, scoliosis, difficulty with mobility, and feeding issues.

Beckwith-Wiedemann Syndrome

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Imprinting Disorders

Symptoms:
overgrowth; macroglossia (enlarged tongue); abdominal wall defects; hypoglycemia in infancy; ear creases or pits; hemihyperplasia (asymmetric body growth); increased risk of embryonal tumors (e.g., wilms tumor, hepatoblastoma)

Root Cause:
Disruption of normal imprinting on chromosome 11p15, leading to overexpression or underexpression of growth-regulating genes (e.g., IGF2).

How it's Diagnosed: videos
Clinical evaluation, genetic testing (methylation studies and chromosomal analysis), and screening for associated tumors.

Treatment:
Regular monitoring for tumors, management of hypoglycemia, surgical correction of macroglossia or abdominal wall defects, and supportive care for overgrowth-related issues.

Medications:
No specific medications; supportive care with glucose supplementation for hypoglycemia if needed.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 13,700 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Increased incidence in children conceived through assisted reproductive technologies (ART), although most cases are sporadic.

Prognosis: The expected outcome or course of the condition over time.
With proper management, most individuals have a normal life expectancy. Regular cancer surveillance is critical in childhood.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Tumor development, feeding difficulties, respiratory issues (due to macroglossia), and orthopedic complications from overgrowth.

Silver-Russell Syndrome

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Imprinting Disorders

Symptoms:
severe intrauterine growth restriction (iugr); failure to thrive; triangular facial appearance; asymmetry of the limbs or body; feeding difficulties; short stature; delayed bone age

Root Cause:
Disruption of normal imprinting on chromosome 11p15 or maternal uniparental disomy of chromosome 7; affects growth-regulating genes.

How it's Diagnosed: videos
Clinical evaluation, genetic testing (methylation studies on chromosome 11p15 and chromosome 7).

Treatment:
Growth hormone therapy, nutritional support, and physical therapy to address growth and developmental issues.

Medications:
Growth hormone therapy (to improve height and growth); no specific medications beyond supportive care.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 30,000 to 1 in 100,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
No specific risk factors beyond genetic inheritance patterns; sporadic occurrence.

Prognosis: The expected outcome or course of the condition over time.
Normal life expectancy with proper management, though short stature and asymmetry may persist.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Feeding difficulties, hypoglycemia, delayed puberty, and psychosocial challenges related to growth delays and physical asymmetry.

Noonan Syndrome

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Growth Disorders

Symptoms:
short stature; distinctive facial features; heart defects; webbed neck; developmental delays; low muscle tone; feeding difficulties in infancy

Root Cause:
Caused by mutations in genes involved in the RAS/MAPK signaling pathway, which is critical for cell division, differentiation, and growth.

How it's Diagnosed: videos
Clinical examination based on physical features and symptoms, genetic testing to confirm mutations in associated genes (e.g., PTPN11, SOS1, RAF1).

Treatment:
Multidisciplinary management addressing specific symptoms; growth hormone therapy for short stature, surgery for heart defects, physical therapy for low muscle tone.

Medications:
Growth hormone therapy (somatropin ) can be prescribed for short stature; it is a recombinant human growth hormone. Other treatments are symptom-specific rather than pharmacological.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 1,000 to 2,500 live births.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of Noonan syndrome (autosomal dominant inheritance); de novo mutations also occur.

Prognosis: The expected outcome or course of the condition over time.
Variable; many individuals have normal life expectancy with management, though some may experience complications from cardiac issues.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Pulmonary valve stenosis, hypertrophic cardiomyopathy, learning disabilities, bleeding disorders, and increased cancer risk.

Russell-Silver Syndrome

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Growth Disorders

Symptoms:
short stature; triangular-shaped face; body asymmetry; feeding difficulties; delayed bone age; hypoglycemia; micrognathia

Root Cause:
Abnormalities in genes regulating growth, often involving changes in chromosome 11p15 or maternal uniparental disomy of chromosome 7.

How it's Diagnosed: videos
Clinical evaluation based on characteristic features, genetic testing for epigenetic or chromosomal abnormalities.

Treatment:
Growth hormone therapy to improve height, nutritional support for feeding difficulties, and management of hypoglycemia.

Medications:
Growth hormone therapy (somatropin ) is often prescribed for short stature.

Prevalence: How common the health condition is within a specific population.
Estimated to occur in 1 in 30,000 to 100,000 live births.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Familial cases are rare; most are sporadic, linked to epigenetic and chromosomal changes.

Prognosis: The expected outcome or course of the condition over time.
Generally good with appropriate management, though stature often remains below average. Cognitive development is typically unaffected.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Feeding problems, delayed motor development, scoliosis, and hypoglycemia.

Weaver Syndrome

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Growth Disorders

Symptoms:
accelerated growth in infancy; macrocephaly; distinctive facial features; joint laxity; intellectual disability; hypotonia; skeletal abnormalities

Root Cause:
Caused by mutations in the EZH2 gene, which is involved in chromatin remodeling and gene expression.

How it's Diagnosed: videos
Clinical examination of growth and developmental patterns, genetic testing for EZH2 mutations.

Treatment:
Supportive care for developmental delays, physical therapy for joint and muscle issues, orthopedic interventions for skeletal abnormalities.

Medications:
No specific medications are used for Weaver syndrome; treatment is symptomatic and supportive.

Prevalence: How common the health condition is within a specific population.
Extremely rare, with only a few hundred cases reported worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Typically occurs sporadically due to de novo mutations, though familial cases with autosomal dominant inheritance are possible.

Prognosis: The expected outcome or course of the condition over time.
Highly variable depending on the severity of symptoms and associated complications; intellectual disability may impact long-term outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Joint problems, scoliosis, delayed motor development, and increased risk of certain cancers.

Usher syndrome (hearing and vision loss)

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Sensory Disorders

Symptoms:
hearing loss; progressive vision loss (night blindness, tunnel vision); balance issues in some cases

Root Cause:
Mutations in genes affecting the development and function of the inner ear and retina, leading to sensorineural hearing loss and retinitis pigmentosa.

How it's Diagnosed: videos
Clinical examination, hearing tests, visual field tests, electroretinography, genetic testing for causative mutations.

Treatment:
No cure; management includes hearing aids, cochlear implants, vision aids, orientation and mobility training, and counseling.

Medications:
No specific medications treat the syndrome directly, but supplements like vitamin A palmitate may slow vision loss in some patients.

Prevalence: How common the health condition is within a specific population.
Estimated to affect 4 to 17 in 100,000 people worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, particularly autosomal recessive inheritance patterns.

Prognosis: The expected outcome or course of the condition over time.
Progressive hearing and vision loss over time; early intervention can improve quality of life.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Total blindness, profound hearing loss, and impaired mobility due to balance issues.

Alport syndrome (hearing loss, kidney disease)

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Multisystem Disorders

Symptoms:
hematuria (blood in urine); progressive hearing loss; proteinuria; kidney failure; ocular abnormalities in some cases

Root Cause:
Mutations in the COL4A3, COL4A4, or COL4A5 genes affecting type IV collagen, a structural component of the kidneys, cochlea, and eyes.

How it's Diagnosed: videos
Urinalysis, kidney biopsy, audiometry, eye examinations, and genetic testing.

Treatment:
Management includes blood pressure control, ACE inhibitors to slow kidney damage, hearing aids, and eventually dialysis or kidney transplantation for kidney failure.

Medications:
ACE inhibitors and ARBs (angiotensin receptor blockers) are the primary medications to slow kidney disease progression.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 50,000 newborns.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of Alport syndrome or related kidney diseases.

Prognosis: The expected outcome or course of the condition over time.
Kidney failure often occurs by the second or third decade of life in males; milder symptoms in females. Hearing aids and kidney transplantation can improve outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
End-stage renal disease, deafness, and eye abnormalities such as anterior lenticonus or corneal erosions.

Retinitis pigmentosa

Specialty: Genetics

Category: Other Genetic Syndromes

Sub-category: Sensory Disorders

Symptoms:
night blindness; progressive loss of peripheral vision; eventual loss of central vision in advanced stages

Root Cause:
Mutations in over 100 genes responsible for photoreceptor and retinal pigment epithelial function, leading to degeneration of rods and cones in the retina.

How it's Diagnosed: videos
Clinical examination, fundus photography, electroretinography, visual field testing, and genetic testing.

Treatment:
No cure; management includes low-vision aids, orientation and mobility training, and possibly gene therapy in the future.

Medications:
High-dose vitamin A palmitate may slow progression in some patients. Emerging treatments include gene therapy and retinal implants (in trials).

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 4,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, particularly autosomal dominant, recessive, or X-linked inheritance patterns.

Prognosis: The expected outcome or course of the condition over time.
Gradual progression to blindness, but some maintain central vision into later adulthood. Experimental therapies hold promise.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Blindness, psychological effects, and reduced mobility and independence.